Washington: A recent study from the Allen Institute and Fred Hutchinson Cancer Centre suggested that the cause of many protracted COVID cases may be an excessive inflammatory response. When researchers examined proteins in the blood, they discovered a group of chemicals linked to inflammation that were only detectable in a small subgroup of patients with extended COVID and were not present in those who recovered from their condition. Today, the scientists wrote a paper for the journal Nature Communications outlining their findings.
About two-thirds of the 55 patients with extended COVID exhibited chronically elevated levels of certain inflammation-related markers. Additionally, the researchers examined blood samples from 25 COVID-positive individuals who recovered and from 25 healthy participants. People lacking lengthy COVID did not exhibit the same blood inflammatory symptoms.
Also Read: Long COVID Has A Negative Impact On General Wellness Of People: Study
The patient volunteers in the new analysis are part of a larger, ongoing study based at Fred Hutch, the Seattle COVID Cohort Study, which is led by Julie McElrath, M.D., Ph.D., Senior Vice President and Director of Fred Hutch’s Vaccine and Infectious Disease Division, and Julie Czartoski, ARNP, Research Clinician at the Hutch.
Scientists have seen previous links between inflammation and long COVID, but the new study is the first to trace the persistence of these inflammatory markers over time in the same patients.
There’s an obvious implication to these findings, said Troy Torgerson, M.D., Ph.D., Director of Experimental Immunology at the Allen Institute for Immunology, a division of the Allen Institute: Certain kinds of anti-inflammatory drugs might alleviate symptoms for some long COVID patients. But physicians need a way of telling which long COVID patients might benefit from which treatment — a form of precision medicine for a disease that so far remains maddeningly mysterious.
The big question was, can we define which long COVID patients have persistent inflammation versus those that don’t? That would be useful in terms of clinical trial planning and in terms of helping clinicians figure out targeted treatments for their patients, said Torgerson, who led the Nature Communications publication along with McElrath, Aarthi Talla, Senior Bioinformatician at the Allen Institute for Immunology, Suhas Vasaikar, Ph.D., former Senior Bioinformatics Scientist (now a Principal Scientist at Seagen), and Tom Bumol, Ph.D., former Executive Vice President and Director.
Specifically, the blood markers uncovered in this subset of patients with “inflammatory long COVID,” as the scientists call it, point to a flavor of inflammation similar to that seen in autoimmune diseases like rheumatoid arthritis. This kind of inflammation can be treated with an existing class of drugs called JAK inhibitors, at least in the case of rheumatoid arthritis (it has not yet been tested for long COVID).
The scientists also hope to narrow down their molecular signature of “inflammatory long COVID” to a few markers that could be used in the clinic to sort this subset of long COVID patients out from the rest.
Launched in the spring of 2020, shortly after the COVID-19 pandemic shut down businesses and schools in the U.S., the Fred Hutch-led Seattle COVID Cohort Study was originally designed to follow immune responses over time in patients with mild or moderate COVID. The idea was to capture details of a “successful” immune response — one in which patients didn’t get too sick, didn’t need to be hospitalized, and recovered fully.
But the team soon realized that even among those who didn’t get super sick, not everyone recovered. In their initial work in 2020 tracing the details of immune responses in 18 COVID patients, the scientists found a handful whose symptoms persisted, early examples of what would eventually be termed long-haul COVID, or just long COVID.
In those early days of the study, the scientists saw that certain immune responses — namely inflammation — were consistently high in these few patients with long COVID. In the patients that got sick and then recovered fully, inflammation levels went up as their bodies fought off the illness, and then went back down as they got better. In those with long COVID, the levels never went back down.
So the team decided to expand their study to look at more patients with long COVID, focusing on a panel of 1500 proteins circulating in the blood. These assays revealed different molecular “buckets” of long COVID, namely inflammatory and non-inflammatory long COVID. Understanding the molecular roots of the disease, or subsets of the disease, will help guide clinical trial design and ultimately treatment decisions, the scientists said. Ms. Talla said,
The ultimate goal is to treat patients. Although we call everything long COVID, what’s come out of this work shows us that we might not be able to give everyone the same kinds of therapies and we shouldn’t put everyone into one group for treatment purposes.
Those patients with non-inflammatory long COVID might be living with permanent organ or tissue damage from their disease, Torgerson said. That would require very different treatment from those with high levels of inflammation. The scientists also saw that these groups can’t be distinguished based on symptoms alone. If anti-inflammatory drugs prove effective in treating inflammatory long COVID, patients would first need to be screened to determine which form of long COVID they have.
We hope these findings provide features of long COVID that may guide potential future therapeutic approaches, Ms. McElrath said.
Also Read: Long Covid Can Impact Quality Of Life More Than Some Cancers: Study
(This story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol have been working towards a clean and healthy India since 2014 via the Banega Swachh India initiative, which is helmed by Campaign Ambassador Amitabh Bachchan. The campaign aims to highlight the inter-dependency of humans and the environment, and of humans on one another with the focus on One Health, One Planet, One Future – Leaving No One Behind. It stresses on the need to take care of, and consider, everyone’s health in India – especially vulnerable communities – theLGBTQ population,indigenous people, India’s different tribes, ethnic and linguistic minorities, people with disabilities, migrants, geographically remote populations, gender and sexual minorities. In wake of the currentCOVID-19 pandemic, the need for WASH (Water,SanitationandHygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign will continue to raise awareness on the same along with focussing on the importance of nutrition and healthcare for women and children, fightmalnutrition, mental wellbeing, self care, science and health,adolescent health & gender awareness. Along with the health of people, the campaign has realised the need to also take care of the health of the eco-system. Our environment is fragile due to human activity, which is not only over-exploiting available resources, but also generating immense pollution as a result of using and extracting those resources. The imbalance has also led to immense biodiversity loss that has caused one of the biggest threats to human survival – climate change. It has now been described as a “code red for humanity.” The campaign will continue to cover issues likeair pollution,waste management,plastic ban,manual scavengingand sanitation workers andmenstrual hygiene. Banega Swasth India will also be taking forward the dream of Swasth Bharat, the campaign feels that only a Swachh or clean India wheretoiletsare used andopen defecation free (ODF)status achieved as part of the Swachh Bharat Abhiyan launched byPrime Minister Narendra Modiin 2014, can eradicate diseases like diahorrea and the country can become a Swasth or healthy India.
